A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2, 2026

more

A.I. Burnasyan  FMBC clinical bulletin. 2026 № 2

V.S. Blinov1, Yu.D. Udalov2, Yu.S. Kitaeva3, M.D. Lobova2, E.V. Kuznetsova4

A Study the Prevalence of Vertebral Fractures in Patients with Hodgkin’s Lymphoma
and its Association with Bone Mineral Density Assessed by Dual-Energy X-Ray Absorptiometry

1Verkhnepyshminskaya Central City Clinical Hospital named after P.D. Borodin Department of X-ray diagnostics Verkhnyaya Pyshma, Russia

2International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа

3Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation, Moscow, Russiа

4Federal State Budgetary Educational Institution of Higher Education, Ural State Medical University of the Ministry of Health of Russia, Yekaterinburg, Russiа

Contact person: Kitaeva Julya Sergeevna: jkhema@yandex.ru

 

Abstract
Background: Phpatients with Hodgkin lymphoma are young, socially active individuals with a long life expectancy. However, the occurrence of late treatment complications, such as osteoporosis, is a concern.
Objective: to determine the prevalence of vertebral fractures in patients with Hodgkin lymphoma and determine its association with osteoporosis.
Material and methods: CT, PET/CT, and densitometry results were analyzed in patients with Hodgkin lymphoma and a group of healthy controls. Inclusion criteria for the study group were: diagnosis of Hodgkin lymphoma; therapy including glucocorticosteroids; and a CT and/or PET/CT series over at least 1 year. Exclusion criteria: specific bone lesions.
Result: vertebral fractures were detected in 47% of women and 41% of men. Fractures of two or more vertebrae were the most common (62% and 67%, respectively). The average number of vertebral fractures per patient was 2.2. Genant grade 1 fractures were the most common (59%). In 27% of cases, the severity of vertebral fractures increased during the observation period. In the control group, vertebral fractures were detected in 15% of cases. 80% of patients had single vertebral fractures, and 20% had double vertebral fractures. All fractures were Genant grade 1. Of 14 men and 22 women with Hodgkin lymphoma and vertebral fractures, only 1 man (7%) and 4 women (18%) showed a decrease in BMD on DXA.
Conclusions: a significant prevalence of vertebral fractures was found in patients with Hodgkin lymphoma. The prevalence of vertebral fractures increases sharply from disease onset to and during remission. BMD in patients with Hodgkin lymphoma, measured by DXA, has a weak relationship with the prevalence of vertebral fractures in this patient group.

Keywords: osteoporosis, Hodgkin’s lymphoma, computed tomography, vertebral fractures, positron emission tomography

For citation: Blinov VS, Udalov YuD, Kitaeva YuS, Lobova MD, Kuznetsova EV. A Study the Prevalence of Vertebral Fractures in Patients with Hodgkin’s Lymphoma and its Association with Bone Mineral Density Assessed by Dual-Energy X-Ray Absorptiometry. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2026.2:93-98. (In Russian) DOI: 10.33266/2782-6430-2026-2-93-98

 

REFERENCES

  1. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность) / Под ред. А.Д.Каприна и др. М.: Московский научно-исследовательский онкологический институт им. П.А. Герцена, 2024. 276 с. ISBN 978-5-85502-298-8 [Zlokachestvennyye Novoobrazovaniya v Rossii v 2023 Godu (Zabolevayemost‘ i Smertnost‘) = Malignant Neoplasms in Russia in 2023 (Incidence and Mortality). Ed. A.D. Kaprin, et al. Moscow, Moskovskiy Nauchno-Issledovatel’skiy Onkologicheskiy Institut im. P.A. Gertsena Publ., 2024. 276 p. (In Russ.)]. ISBN 978-5-85502-298-8.
  2. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer Statistics, 2023. CA Cancer J Clin. 2023;73;1:17-48. Doi: 10.3322/caac.21763.
  3. Engert A., Diehl V., Franklin J., Lohri A., Dörken B., Ludwig W.-D., Koch P., Hänel M., Pfreundschuh M., Wilhelm M., Trümper L., Aulitzky W.-E., Bentz M., Rummel M., Sezer O. Müller-Hermelink H.-K., Hasenclever D., Löffler M. Escalated-Dose BEACOPP in the Treatment of Patients with Advanced-Stage Hodgkin’s Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study. J Clin Oncol. 2009;27;27:4548–54. Doi: 10.1200/JCO.2008.19.8820.
  4. Arden-Close E., Pacey A., Eiser C. Health-Related Quality of Life in Survivors of Lymphoma: a Systematic Review and Methodological Critique. Leuk Lymphoma. 2010;51;4:628–40. Doi: 10.3109/10428191003587263.
  5. Compaci G., Conte C., Oberic L., Ysebaert L., Laurent G., Despas F. Sustained Degradation of Quality of Life in a Subgroup of Lymphoma Survivors: a Two-Year Prospective Survey. BMC Cancer. 2019;19;1:1178. Doi: 10.1186/s12885-019-6337-2.
  6. Adams M.J., Lipsitz S.R., Colan S.D., Tarbell N.J., Treves S.T., Diller L. Cardiovascular Status in Long-Term Survivors of Hodgkin’s Disease Treated with Chest Radiotherapy. J Clin Oncol. 2004;22;15:3139–48. Doi: 10.1200/JCO.2004.09.109.
  7. Fayette D., Jurı́čková V., Kozák T., Mociková H., Gaherová L., Fajnerová I. Cognitive Impairment Associated with Hodgkin’s Lymphoma and Chemotherapy. Neurosci Lett. 2023;797:137082. Doi: 10.1016/j.neulet.2023.137082.
  8. Gebauer J., Fick E.-M., Waldmann A., Langer T., Kreitschmann-Andermahr I., Lehnert H., Katalinic A., Brabant G. Self-Reported Endocrine Late Effects in Adults Treated for Brain Tumours, Hodgkin and Non-Hodgkin Lymphoma: a Registry Based Study in Northern Germany. Eur J Endocrinol. 2015;173:139–148.
  9. Shanbhag S., Ambinder R.F. Hodgkin Lymphoma: a Review and Update on Recent Progress. CA Cancer J Clin. 2018;68;2:116–32. Doi: 10.3322/caac.21438.
  10. André M.P.E., Carde P., Viviani S., Bellei M., Fortpied C., Hutchings M., et al. Longterm Overall Survival and Toxicities of ABVD vs BEACOPP in Advanced Hodgkin Lymphoma: a Pooled Analysis of four Randomized Trials. Cancer Med. 2020;9;18:6565–75. Doi: 10.1002/cam4.3298.
  11. Di Molfetta S., Daniele A., Gerardi C., Allocati E., Minoia C., Loseto G., Giorgino F., Guarini A., De Sanctis V. Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: a Systematic Review by the Fondazione Italiana Linfomi. Cancers. 2022;14;6:1439. Doi: 10.3390/cancers14061439.
  12. Loffler M.T., Jacob A., Scharr A. Automatic Opportunistic Osteoporosis Screening in Routine CT: Improved Prediction of Patients with Prevalent Vertebral Fractures Compared to DXA. Eur Radiol. 2021;31:6069–6077. Doi: 10.1007/s00330-020-07655-2.
  13. Ballane G., Cauley J.A., Luckey M.M., Fuleihan G. Worldwide Prevalence and Incidence of Osteoporotic Vertebral Fractures. Osteopor Int. 2017;28:1531–42. Doi: 10.1007/s00198-017-3909-3.
  14. Baech J., Hansen S.M., Jakobsen L.H., Øvlisen A.K., Severinsen M.T., Brown PdeN., El-Galaly T.C. Increased Risk of Osteoporosis Following Commonly Used First-Line Treatments for Lymphoma: a Danish Nationwide Cohort Study. Leukemia & Lymphoma. 2020;61;6:1345–1354. Doi: 10.1080/10428194.2020.1723015.
  15. Svendsen P., Shekhrajka N., Lindblad Nielsen K., Vestergaard P., Østergaard Poulsen M., Krog Vistisen A., Svenssen Munksgaard P. R-CHOP(-Like) Treatment of Diffuse Large B-Cell Lymphoma Significantly Reduces CT-Assessed Vertebral Bone Density: A Single Center Study of 111 Patients. Leukemia & Lymphoma. 2016;58;5:1105–13. Doi: 10.1080/10428194.2016.1233543.
  16. Armas L.A., Recker R.R. Pathophysiology of Osteoporosis: New Mechanistic Insights. Endocrinol Metab Clin North Am. 2012;41;3:475–86. Doi: 10.1016/j.ecl.2012.04.006.
  17. Compston J.E. Management of Glucocorticoid-Induced Osteoporosis. Nature Rev. Rheumatol. 2010;6:82–88. Doi: 10.1038/nrrheum.2009.259.
  18. Staa van T.P., Leufkens H.G., Cooper C. The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-Analysis. Osteoporos Int. 2002;13:777–787. Doi: 10.1007/s001980200108.
  19. Hui K., Arentsen L., Sueblinvong T. A Phase I Feasibility Study of Multi-Modality Imaging Assessing Rapid Expansion of Marrow Fat and Decreased Bone Mineral Density in Cancer Patients. Bone. 2015;73:90–97. Doi: 10.1016/j.bone.2014.12.014.
  20. Genant H.K., Wu C.Y., Kuijk C. Vertebral Fracture Assessment Using a Semiquantitative Technique. J Bone Miner Res. 1993;8:1137–1148.
  21. Royer B., Charbonnier A., Ursu D. Alterations in Bone Mineral Density and Bone Turnover Markers in Newly Diagnosed Adults with Lymphoma Receiving Chemotherapy: a 1-Year Prospective Pilot Study. Ann Oncol. 2014;25:481–486. Doi: 10.1093/annonc/mdt560.
  22. Kim S.H., Lim S.K., Hahn J.S. Effect of Pamidronate on New Vertebral Fractures and Bone Mineral Density in Patients with Malignant Lymphoma Receiving Chemotherapy. Am. J. Med. 2004;116:524–528. Doi: 10.1016/j.amjmed.2003.12.019.
  23. Huang L.W., Sun D., Link T.M. High Incidence of Fractures after R-CHOP-Like Chemotherapy for Aggressive B-Cell Non-Hodgkin Lymphomas. Support Care Cancer. 2021;29:5399–5408. Doi: 10.1007/s00520-021-06120-0.
  24. Ruchlemer R., Amit-Kohn M., Tvito A., Sindelovsky I., Zimran A., Raveh-Brawer D. Bone Loss and Hematological Malignancies in Adults: a Pilot Study. Support Care Cancer. 2018;26:3013–3020. Doi: 10.1007/s00520-018-4143-z.
  25. Buckley L., Guyatt G., Fink H.A., Cannon M., Grossman J., Hansen K.E., Humphrey M.B., Lane N.E., Magrey M., Miller M., Morrison L., Rao M., Robinson A.B., Saha S., Wolver S., Bannuru R.R., Vaysbrot E., Osani M., Turgunbaev M., Miller A.S., McAlindon T. American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69;8:1521–1537. Doi: 10.1002/art.40137.
  26. Праскурничий Е.А., Китаева Ю.С. Ассоциированные с патогенетической терапией лимфомы Ходжкина факторы риска остеопороза и остеопении // Кремлевская медицина. Клинический вестник. 2022. №4. С. 5 – 8 [Praskurnichiy Ye.A., Kitayeva Yu.S. Risk Factors for Osteoporosis and Osteopenia Associated with Pathogenetic Therapy of Hodgkin’s Lymphoma. Kremlevskaya Meditsina. Klinicheskiy Vestnik = Kremlin Medicine Journal. 2022;4:5–8 (In Russ.)].
  27. Китаева Ю.С., Праскурничий Е.А. Алгоритм оценки факторов риска нарушений минеральной плотности костной ткани на фоне патогенетической терапии лимфомы Ходжкина // Сибирское медицинское обозрение. 2023. Т.1. №139. С. 31 – 36 [Kitayeva Yu.S., Praskurnichiy Ye.A. Algorithm for Assessing Risk Factors for Bone Mineral Density Disorders during Pathogenetic Therapy for Hodgkin’s Lymphoma. Sibirskoye Meditsinskoye Obozreniye = Siberian Medical Review. 2023;1;139:31–36 (In Russ.)].
  28. Бадыкова К.М., Китаева Ю.С., Праскурничий Е.А., Нагиева А.Р., Кузнецова Е.В. Факторы риска снижения минеральной плотности костной ткани у пациентов с лимфомой Ходжкина // Российский медицинский журнал. 2024 Т.30. №5 С. 475-485 [Badykova K.M., Kitayeva Yu.S., Praskurnichiy Ye.A., Nagiyeva A.R., Kuznetsova Ye.V. Risk Factors for Decreased Bone Mineral Density in Patients with Hodgkin’s Lymphoma. Rossiyskiy Meditsinskiy Zhurnal = Russian Medical Journal. 2024;30;5:475-485 (In Russ.)].
  29. Бадыкова К.М., Китаева Ю.С., Праскурничий Е.А. Особенности денситометрической оценки костной ткани у молодых пациентов с лимфомой Ходжкина // Архивъ внутренней медицины. 2024. Т.14. №3. С. 173-180 [Badykova K.M., Kitayeva Yu.S., Praskurnichiy Ye.A. Features of Densitometric Assessment of Bone Tissue in Young Patients with Hodgkin’s Lymphoma. Arkhiv» Vnutrenney Meditsiny = Archiv of Internal Medicine. 2024;14;3:173-180 (In Russ.)].
  30. Китаева Ю.С., Праскурничий Е.А. Алгоритм оценки факторов риска нарушений минеральной плотности костной ткани на фоне патогенетической терапии лимфомы Ходжкина // Сибирское медицинское обозрение. 2023. №1. С. 31-36 [Kitayeva Yu.S., Praskurnichiy Ye.A. Algorithm for Assessing Risk Factors for Bone Mineral Density Disorders during Pathogenetic Therapy of Hodgkin’s Lymphoma. Sibirskoye Meditsinskoye Obozreniye = Siberian Medical Review. 2023;1:31-36 (In Russ.)].
  31. Schuit S.C., van der Klift M., Weel A.E., de Laet C.E., Burger H., Seeman E., Hofman A., Uitterlinden A.G., van Leeuwen J.P., Pols H.A. Fracture Incidence and Association with Bone Mineral Density in Elderly Men and Women: the Rotterdam Study. Bone. 2004;34;1:195–202. Doi: 10.1016/j.bone.2003.10.001.
  32. Mancuso S., Scaturro D., Santoro M. Bone Damage after Chemotherapy for Lymphoma: a Real-World Experience. BMC Musculoskelet Disord. 2021;22:1024. Doi: 10.1186/s12891-021-04904-3.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 14.04.2026. Accepted for publication: 28.04.2026

© 2026 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top